Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders

 
 

Arsanis, Inc. (ASNS) Add to portfolio

1m | 3m | 6m | 1y | 2y | 5y | 10yArsanis Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of monoclonal antibodies for the targeted immunotherapy of serious infections.

CEO: Rene Russo
http://www.arsanis.com
Price: $16.53 Metrics
OS: 14.3 M
Market cap: $236 M
Net cash: $40 M $2.80 per share
EV: $196 M

 
TTM Valuation
EBITDA
EBIT
EPS

Recent News + Filings   (All items)

Financial Summary   (All financials)
In millions, except per share itemsDec-31-17Dec-31-16Dec-31-15
Revenues28.117.812.7
            Revenue growth57.7%40.3% 
Cost of goods sold36.124.314.8
Gross profit-8.0-6.5-2.1
            Gross margin-28.5%-36.5%-16.7%
General and administrative8.06.52.1
EBIT-36.1-24.3-14.8
            EBIT margin-128.5%-136.5%-116.7%
Pre-tax income-33.9-23.0-13.2
Income taxes0.00.00.0
            Tax rate0.0%0.0%0.0%
Net income0.00.00.0
            Net margin-0.1%-0.1%-0.1%
 
Diluted EPS($16.45)($44.79)($26.02)
Shares outstanding (diluted)0.00.00.0
 
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.

Rocket Data Systems, Inc. © 2018 | Contact Us | Data Disclaimer | Terms of Use | Privacy